Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children:: Epidemiology and clinical outcome

被引:276
作者
Kim, YK
Pai, H
Lee, HJ
Park, SE
Choi, EH
Kim, J
Kim, JH
Kim, EC
机构
[1] Seoul Natl Univ, Dept Pediat, Coll Med, Seoul, South Korea
[2] Seoul Natl Univ, Dept Clin Pathol, Coll Med, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Clin Res Inst, Seoul 110744, South Korea
[4] Dankook Univ, Dept Internal Med, Coll Med, Cheonan, South Korea
[5] Dankook Univ, Dept Microbiol, Coll Med, Cheonan, South Korea
[6] Cheil Jedang Corp, Inst Sci & Technol, Ichon, South Korea
关键词
D O I
10.1128/AAC.46.5.1481-1491.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
To determine the epidemiologic features and clinical outcomes of bloodstream infections caused by extended-spectrum P-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates, cases of bacteremia caused by these organisms in children were analyzed retrospectively. Among the 157 blood isolates recovered from 1993 to 1998 at the Seoul National University Children's Hospital, the prevalence of ESBL production was 17.9% among the E. coli isolates and 52.9% among the K. pneumoniae isolates. The commonest ESBLs were SRV-2a and TEM-52. A novel ESBL, TEM-88, was identified. Pulsed-field gel electrophoresis analysis of the ESBL-producing organisms showed extensive diversity in clonality. The medical records of 142 episodes were reviewed. The risk factors for bloodstream infection with ESBL-producing organisms were prior hospitalization, prior use of oxyimino-cephalosporins, and admission to an intensive care unit within the previous month. There was no difference in clinical severity between patients infected with ESBL-producing strains (the ESBL group) and those infected with ESBL-nonproducing strains (the non-ESBL group) at the time of presentation. However, the overall fatality rate for the ESBL group was significantly higher than that for the non-ESBL group: 12 of 45 (26.7%) versus 5 of 87 (5.7%) (P = 0.001). In a subset analysis of patients treated with extended-spectrum cephalosporins with or without an aminoglycoside, favorable response rates were significantly higher in the non-ESBL group at the 3rd day (6 of 17 versus 33 of 51; P = 0.035), the 5th day (6 of 17 versus 36 of 50; P < 0.05), and the end of therapy (9 of 17 versus 47 of 50; P < 0.001). In conclusion, the ESBL production of the infecting organisms has a significant impact on the clinical course and survival of pediatric patients with bacteremia caused by E. coli and K. pneumoniae.
引用
收藏
页码:1481 / 1491
页数:11
相关论文
共 36 条
  • [1] A STANDARD NUMBERING SCHEME FOR THE CLASS-A BETA-LACTAMASES
    AMBLER, RP
    COULSON, AFW
    FRERE, JM
    GHUYSEN, JM
    JORIS, B
    FORSMAN, M
    LEVESQUE, RC
    TIRABY, G
    WALEY, SG
    [J]. BIOCHEMICAL JOURNAL, 1991, 276 : 269 - 270
  • [2] Ariffin H, 2000, Int J Infect Dis, V4, P21, DOI 10.1016/S1201-9712(00)90061-4
  • [3] Sequences of p-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases
    Bauernfeind, A
    Stemplinger, I
    Jungwirth, R
    Ernst, S
    Casellas, JM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (02) : 509 - 513
  • [4] NOVEL R-FACTOR BORNE BETA-LACTAMASE OF ESCHERICHIA-COLI CONFERING RESISTANCE TO CEPHALOSPORINS
    BAUERNFEIND, A
    HORL, G
    [J]. INFECTION, 1987, 15 (04) : 257 - 259
  • [5] MOLECULAR EPIDEMIOLOGY OF PLASMID SPREAD AMONG EXTENDED BROAD-SPECTRUM BETA-LACTAMASE-PRODUCING KLEBSIELLA-PNEUMONIAE ISOLATES IN A PEDIATRIC HOSPITAL
    BINGEN, EH
    DESJARDINS, P
    ARLET, G
    BOURGEOIS, F
    MARIANIKURKDJIAN, P
    LAMBERTZECHOVSKY, NY
    DENAMUR, E
    PHILIPPON, A
    ELION, J
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (02) : 179 - 184
  • [6] Nomenclature of TEM beta-lactamases
    Bush, K
    Jacoby, G
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (01) : 1 - 3
  • [7] CRAIG WA, 1991, SCAND J INFECT DIS, P63
  • [8] OXA-15, an extended-spectrum variant of OXA-2 beta-lactamase, isolated from a Pseudomonas aeruginosa strain
    Danel, F
    Hall, LMC
    Gur, D
    Livermore, DM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (04) : 785 - 790
  • [9] Farmer JJ, 1999, MANUAL CLIN MICROBIO, P442